February 2020
Price: £95 PLUS VAT
Format: DOWNLOADABLE PDF
The conference was a timely opportunity to discuss the next steps for NICE - looking at:
- Developing evidence-based guidelines;
- The impact of NICE’s recommendations on decision-making; and
- The role of NICE in accelerating the uptake of innovation.
The conference took place in light of the publication of the Life Sciences Sector Deal 2, which committed to making additional funding available to NICE and increasing the number of evaluations of digital products.
It also followed the introduction of the Voluntary Scheme for Branded Medicines Pricing and Access, which included plans to provide faster assessments of the clinical and cost-effectiveness of new medicines.
Keynote speakers included: Meindert Boysen, Director, Centre for Health Technology Evaluation, NICE and Professor Gillian Leng, Deputy Chief Executive and Director of Health and Social Care, NICE.
Further speakers: Professor Andrew Briggs, London School of Hygiene & Tropical Medicine; Professor Matthew Cripps, NHS England and NHS Improvement; Dr Alan MacDonald, Scottish Medicines Consortium; Hilary Hutton-Squire, Gilead Sciences and Doris-Ann Williams, BIVDA - as well as Caroline Cake, Health Data Research UK; Emily Crossley, Duchenne UK; Professor Shanaya Rathod, Wessex Academic Health Sciences Network and Luella Trickett, ABHI.
Chaired by: Anne Marie Morris MP and Professor Hilary Thomas, Chief Medical Adviser and Member, Centre of Excellence in Healthcare and Life Sciences, KPMG.
The agenda
- Priorities for NICE and the policy landscape for health and social care;
- Measuring the impact of NICE guidelines, utilising data, and improving patient and public engagement;
- Challenges for accelerating the uptake of innovative medicines and medical technologies:
- Future funding arrangements as NICE expands;
- Shared decision-making, patient choice, and NHS collaboration with NICE;
- Developing future guidelines and increasing adoption;
- Priorities for the pharmaceutical industry - access, value, and improving outcomes; and
- Evaluating health technologies - the role of HealthTech Connect.
- Next steps for policy.
